Skip to main content

Table 1 Patients’ demographics

From: Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Variable Dose level 1
(N = 3)
Dose level − 1
(N = 6)
Total
(N = 9)
Age [Years]
 N 3 6 9
 Mean (SD) 62.00 (21.63) 60.17 (7.31) 60.78 (12.30)
 Min 38.0 51.0 38.0
 Median 68.00 59.00 60.00
 Max 80.0 71.0 80.0
 Missing 0 0 0
Gender
 Female 1 (33.33%) 3 (50.00%) 4 (44.44%)
 Male 2 (66.67%) 3 (50.00%) 5 (55.56%)
Ethnicity
 Caucasian 3 (100.00%) 6 (100.00%) 9 (100.00%)
Primary tumour
 Intrahepathic tumour 3 (100.00%) 3 (50.00%) 6 (66.67%)
 Extrahepatic tumour 0 (0.00%) 3 (50.00%) 3 (33.33%)
ECOG
 0 2 (66.67%) 2 (33.33%) 4 (44.44%)
 1 1 (33.33%) 4 (66.67%) 5 (55.56%)
Metastatic disease 3 (100.00%) 6 (100.00%) 9 (100.00%)
Target lesions
 Primary tumour 1 (14.29%) 1 (10.00%) 2 (11.76%)
 Liver 3 (42.86%) 3 (30.00%) 6 (35.29%)
 Lung 2 (28.57%) 2 (20.00%) 4 (23.53%)
 Other lymph nodes 1 (14.29%) 0 (0.00%) 1 (5.88%)
 Peritoneum 0 (0.00%) 1 (10.00%) 1 (5.88%)
 Soft tissues 0 (0.00%) 1 (10.00%) 1 (5.88%)
 Others 0 (0.00%) 2 (20.00%) 2 (11.76%)
  1. SD Standard Deviation